Oxford Cannabinoid Technologies Holdings Plc (OCTHF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in London, United Kingdom. The current CEO is Clarissa Ann Sowemimo-Coker.
OCTHF has IPO date of 2021-10-20, 5 full-time employees, listed on the Other OTC, a market capitalization of $3.05M.
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
